Short answer
Kymera Therapeutics, Inc. (KYMR) filed its Q3 2026 10-Q quarterly report on Oct 29, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $0 (down 100.0% year over year) with net income of −$132M.
Q3 2026 key financials · XBRL
- Revenue
- $0
- −100.0% YoY · −100.0% QoQ
- Net income
- −$132M
- −60.6% YoY · −115.6% QoQ
- EPS (diluted)
- −$1.33
- −41.5% YoY · −114.5% QoQ
Source: XBRL data from the Kymera Therapeutics, Inc. (KYMR) Q3 2026 10-Q on SEC EDGAR. USD.
Kymera Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Collaboration revenue $0 vs $2.8M YoY, down $2.8M
- Net loss $132.0M vs $82.2M YoY, operating loss $147.2M vs $92.5M
- STAT6 highest R&D investment $52.0M vs $17.4M, up $34.7M
- Cash used in operations $220.8M, financing provided $258.8M, net cash increase $16.8M
- Cash, equivalents and marketable securities $1.646B, funding expected into 2029 but additional capital required
Risk Factors
- Newly added BIOSECURE Act risk: Section 851 enacted December 18, 2025, potentially restricting provider relationships and delaying development
- Regulatory risk: FDA staffing cuts, shutdowns, and policy changes could delay IND reviews and product approvals
- Clinical risk: STAT6 and IRF5 programs remain in early clinical development, increasing failure and timeline uncertainty
- Competitive risk: Sanofi, Johnson & Johnson, and Gilead announced STAT6 partnerships
- Financial risk: $1,646 million in cash and securities expected to fund operations into 2029, subject to inaccurate assumptions
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Kymera Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.